Clovis Oncology

Clovis Oncology is an American biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company was founded in 2009 and is headquartered in Boulder, Colorado.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Clovis Oncology balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Clovis Oncology cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Clovis Oncology multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Clovis Oncology profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Clovis Oncology assets
Clovis Oncology cash flows

Clovis Oncology dividend policy

The company doesn't provide dividend
Clovis Oncology news
12.12.2022
Nasdaq will delist Clovis Oncology stock in connection with the company's Chapter 11 bankruptcy filing. Company's securities will cease trading on December 21.
Source: d18rn0p25nwr6d.cloudfront.net
Pictogram next
04.05.2022
Clovis Oncology reported a GAAP loss of $60.169 million for the 3 months of 2022, down 9.2% from $66.277 million in the prior year. Revenue decreased 10% to $34.247 million from $38.053 million a year earlier.
Source: {source} pictogram ir.clovisoncology.com
Pictogram next
23.02.2022
Clovis Oncology's GAAP loss for 2021 was $264.524 million, down 28.4% from $369.212 million in the prior year. Revenue declined 9.6% to $148.757 million from $164.522 million a year earlier.
Source: {source} pictogram ir.clovisoncology.com
Pictogram next
03.11.2021
Clovis Oncology's GAAP loss for 9M 2021 was $200.133 million, down 25.9% from $270.254 million in the prior year. Revenue decreased 7% to $112.789 million from $121.223 million a year earlier.
Source: {source} pictogram ir.clovisoncology.com
Pictogram next
All Clovis Oncology news
General information
Company nameClovis Oncology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address5500 Flatiron Parkway Boulder, CO 80301 United States
Mailing address5500 Flatiron Parkway Boulder, CO 80301 United States
Websiteir.clovisoncology.com
Information disclosurewww.sec.gov